Nasal Naloxone Pharmacokinetics
College of Pharmacy
5/1/2013 – 11/1/2013
This study was a preliminary clinical pharmacokinetic study. Naloxone formulations [(2 mg) intravenous, intramuscular, and intranasal] were compared in six subjects. Intravenous and intramuscular formulations were compared to the novel intranasal formulation (100 & 200 μL/nostril). Plasma was collected at various times (0, 5, 10, 15, 30, 45, 60, 90, 120, 240 min), and naloxone concentrations were measured. The primary goal of this investigation was to examine the relative bioavailability of naloxone between different routes of administration in preparation for a larger study intended to examine the bioequivalency between different routes (e.g., intranasal, intravenous) of administration.